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Naphthalimides (1H-benzo[de]isoquinoline-1,3-(2H)-diones) consists of a flat, generally π-
deficient aromatic or heteroaromatic system and show strong hydrophobicity.1 These types of 
compounds with this moiety showed fluorescence and biological properties such as anticancer, 
antimicrobial, antitrypanosomal, analgesic, antioxidative and antiviral properties1-2 The 
naphthalimides compounds are also known to be very good DNA intercalators3, since the planar 
naphthalimido moiety binds by perpendicular insertion between the base pairs of the double 
helix of DNA.4 Previous work had already shown that mono and bis naphthalimido derivatives to 
exhibit strong activity against different cancer cell lines.5-6 Here in this work we would like to 
demonstrate that the alkyl chain i.e. the linker between the naphthalimido groups or the 
substituent attached at the end of the linker chain, do have an impact on the  biological and 
DNA binding properties. The synthesis of new mono-naphthalimides derivatives involved the 
reaction with different aldehydes and with different length of alkyl chain. For the new bis-
naphthalimides the reactions consist of an N-alkylation reaction between with different linkers 
and the corresponding O-tosyl alkylnaphthalimides. The biological activities of the newly 
synthesized compounds includes their ability to bind DNA, their toxicity against SH-5YSY 
human brain cancer cells in vitro, cell morphology and cellular uptake will also be presented. 
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